Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Evommune, Inc. (EVMN)
USD12.25
+0.26 (+2.17%)
US NYSE Healthcare Biotechnology
Address
1841 Page Mill Road 94304
Palo Alto, CA, US
Palo Alto, CA, US
CEO
Luis C. Pena
Website
evommune.com
IPO
2025-11-06
CIK 1837254 ISIN US30054Y1073
Description
Evommune, Inc. is a United States-based clinical-stage biotechnology company dedicated to advancing novel therapeutic solutions. Their primary focus lies in addressing the underlying mechanisms of chronic inflammatory diseases. Initial clinical development efforts are concentrated on conditions such as chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. The company's investigational portfolio features EVO756, which is being developed for the treatment of chronic spontaneous urticaria (CSU) and atopic dermatitis (AD), and EVO301, intended for atopic dermatitis (AD) and ulcerative colitis (UC). Established in 2020, Evommune operates from its headquarters in Palo Alto, California.
News Sentiment (7d)
Based on only 1 article — low confidence
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD12.25
+0.26 (+2.17%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
630.7K
Beta
0.86
Float Shares
13.81M
Free Float %
97.5%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -2.24% | -1.39% | -15.99% | -28.13% | +24.53% | +32.54% | +12.16% | +12.16% | +12.16% | +12.16% | +12.16% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (3 ratings, all time)
Buy
Price Targets & DCF
Current price
12.25
Low
40.00
+226.5%
Consensus
49.83
+306.8%
Median
48.50
+295.9%
High
65.00
+430.6%
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 2 | 0 |
| Buy | 8 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | 1 |
54.00
+340.8%
|
| Last Year | 9 |
45.44
+270.9%
|
| All Time | 9 |
45.44
+270.9%
|
Quality scores
Altman Z-Score
10.05
Safe zone
Piotroski F-Score
3 / 9
Average
MOAT Score
2 / 10
No MOAT
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
3 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
3 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%+85.7% ★ Q1'26: -100.0% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%+4.0% Q1'26: -33.3% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-646.4%
-
EBIT margin Biotechnology: +0.0%-623.6%
-
ROIC Biotechnology: -16.1%-138.8% Q1'26: -93.7% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+4.8% Q1'26: +11.9% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.03× Q1'26: -0.10× (vs Q1'25)
Valuation Multiples
From
To
Consensus Estimates
| Metric |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 4 Rev. Ana. 8 EPS Ana. |
Dec 2027 6 Rev. Ana. 7 EPS Ana. |
Dec 2028 5 Rev. Ana. 4 EPS Ana. |
Dec 2029 2 Rev. Ana. 2 EPS Ana. |
Dec 2030 2 Rev. Ana. 2 EPS Ana. |
|---|---|---|---|---|---|---|---|
| Revenue |
7.00M
est: 3.00M (+133.3%)
|
13.00M
est: 13.00M (+0.0%)
|
6.65M
6.65M – 6.65M
-48.8% YoY
|
1.03M
1.03M – 1.03M
-84.6% YoY
|
5.77M
5.77M – 5.77M
+462.6% YoY
|
13.96M
13.96M – 13.96M
+142.0% YoY
|
163.85M
163.85M – 163.85M
+1,073.8% YoY
|
| EBITDA |
-65.49M
est: -3.00M (-2,082.9%)
|
-79.68M
est: -13.00M (-512.9%)
|
-6.65M
-6.65M – -6.65M
+48.8% YoY
|
-1.03M
-1.03M – -1.03M
+84.6% YoY
|
-5.77M
-5.77M – -5.77M
-462.6% YoY
|
-13.96M
-13.96M – -13.96M
-142.0% YoY
|
-163.85M
-163.85M – -163.85M
-1,073.8% YoY
|
| EBIT |
-66.77M
est: -3.00M (-2,125.8%)
|
-81.07M
est: -13.00M (-523.6%)
|
-6.65M
-6.65M – -6.65M
+48.8% YoY
|
-1.03M
-1.03M – -1.03M
+84.6% YoY
|
-5.77M
-5.77M – -5.77M
-462.6% YoY
|
-13.96M
-13.96M – -13.96M
-142.0% YoY
|
-163.85M
-163.85M – -163.85M
-1,073.8% YoY
|
| Net Income |
-66.81M
est: -162.30M (+58.8%)
|
-68.87M
est: -75.99M (+9.4%)
|
-102.03M
-183.83M – -70.34M
-34.3% YoY
|
-137.73M
-198.39M – -87.87M
-35.0% YoY
|
-110.17M
-131.49M – -88.84M
+20.0% YoY
|
-140.22M
-140.22M – -140.22M
-27.3% YoY
|
-95.99M
-95.99M – -95.99M
+31.5% YoY
|
| SGA |
11.48M
est: 5.15M (+122.9%)
|
20.03M
est: 22.32M (-10.3%)
|
11.42M
11.42M – 11.42M
-48.8% YoY
|
1.76M
1.76M – 1.76M
-84.6% YoY
|
9.91M
9.91M – 9.91M
+462.6% YoY
|
23.97M
23.97M – 23.97M
+142.0% YoY
|
281.35M
281.35M – 281.35M
+1,073.8% YoY
|
| EPS |
-2.27
est: -5.15 (+55.9%)
|
-2.18
est: -4.75 (+54.1%)
|
-3.06
-5.83 – -2.23
+35.6% YoY
|
-3.40
-6.29 – -2.79
-11.3% YoY
|
-3.54
-4.17 – -2.82
-4.0% YoY
|
-4.45
-4.45 – -4.45
-25.8% YoY
|
-3.05
-3.05 – -3.05
+31.5% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-08 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-07 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-06 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-05 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-04 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-01 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-30 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-29 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-28 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-27 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-24 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-23 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-22 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-21 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-20 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-17 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-16 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-81.86M
OE per share TTM
-2.58
Owner's Yield
-10.61%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
24.9%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
7
Total invested
6.12M
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
7
-52 vs prev Q
New positions
6
Closed positions
58
Increased
7
Reduced
0
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | ANDERA PARTNERS | 1.90M +1.9M (+100.0%) | 32.48B +32.5B (+100.0%) | 6.02% +6.019 pp | 18.39% +18.393 pp | USD17.12 +0.0% | 1 qtrs NEW |
| 2 | — | 215.4K +215.4K (+100.0%) | 3.69B +3.7B (+100.0%) | 0.68% +0.683 pp | 0.50% +0.500 pp | USD17.12 +0.0% | 1 qtrs NEW |
| 3 | EQT FUND MANAGEMENT S.A R.L. | 4.93M +4.9M (+100.0%) | 84.40M +84.4M (+100.0%) | 15.64% +15.638 pp | 7.59% +7.589 pp | USD17.12 +0.0% | 1 qtrs NEW |
| 4 | RA CAPITAL MANAGEMENT, L.P. | 3.46M +3.5M (+100.0%) | 59.21M +59.2M (+100.0%) | 10.97% +10.972 pp | 0.61% +0.607 pp | USD17.12 +0.0% | 1 qtrs NEW |
| 5 | PIVOTAL BIOVENTURE PARTNERS INVESTMENT ADVISOR LLC | 1.93M +1.9M (+100.0%) | 32.99M +33.0M (+100.0%) | 6.11% +6.113 pp | 12.75% +12.754 pp | USD17.12 +0.0% | 1 qtrs NEW |
| 6 | NAN FUNG GROUP HOLDINGS LTD | 1.44M +1.4M (+100.0%) | 24.67M +24.7M (+100.0%) | 4.57% +4.571 pp | 22.08% +22.081 pp | USD17.12 +0.0% | 1 qtrs NEW |
| 7 | JPMORGAN CHASE & CO | 1.31M +1.3M (+100.0%) | 22.41M +22.4M (+100.0%) | 4.15% +4.152 pp | 0.00% +0.001 pp | USD17.12 +0.0% | 1 qtrs NEW |
| 8 | RTW INVESTMENTS, LP | 1.28M +1.3M (+100.0%) | 21.98M +22.0M (+100.0%) | 4.07% +4.072 pp | 0.22% +0.220 pp | USD17.12 +0.0% | 1 qtrs NEW |
| 9 | MARSHALL WACE, LLP | 988.2K +988.2K (+100.0%) | 16.92M +16.9M (+100.0%) | 3.13% +3.135 pp | 0.02% +0.015 pp | USD17.12 +0.0% | 1 qtrs NEW |
| 10 | EVENTIDE ASSET MANAGEMENT, LLC | 961.5K +961.5K (+100.0%) | 16.46M +16.5M (+100.0%) | 3.05% +3.050 pp | 0.26% +0.257 pp | USD17.12 +0.0% | 1 qtrs NEW |
| 11 | PRICE T ROWE ASSOCIATES INC /MD/ | 782.1K +782.1K (+100.0%) | 13.39M +13.4M (+100.0%) | 2.48% +2.481 pp | 0.00% +0.001 pp | USD17.12 +0.0% | 1 qtrs NEW |
| 12 | SECTORAL ASSET MANAGEMENT INC | 589.0K +589.0K (+100.0%) | 10.08M +10.1M (+100.0%) | 1.87% +1.868 pp | 8.08% +8.083 pp | USD17.12 +0.0% | 1 qtrs NEW |
| 13 | VERITION FUND MANAGEMENT LLC | 565.2K +565.2K (+100.0%) | 9.68M +9.7M (+100.0%) | 1.79% +1.793 pp | 0.04% +0.038 pp | USD17.12 +0.0% | 1 qtrs NEW |
| 14 | ABRDN PLC | 525.4K +525.4K (+100.0%) | 8.99M +9.0M (+100.0%) | 1.67% +1.667 pp | 0.01% +0.014 pp | USD17.12 +0.0% | 1 qtrs NEW |
| 15 | VELAN CAPITAL INVESTMENT MANAGEMENT LP | 506.8K +506.8K (+100.0%) | 8.68M +8.7M (+100.0%) | 1.61% +1.608 pp | 5.03% +5.033 pp | USD17.12 +0.0% | 1 qtrs NEW |
| 16 | VANGUARD GROUP INC | 502.6K +502.6K (+100.0%) | 8.60M +8.6M (+100.0%) | 1.59% +1.594 pp | 0.00% +0.000 pp | USD17.12 +0.0% | 1 qtrs NEW |
| 17 | OCTAGON CAPITAL ADVISORS LP | 500.0K +500.0K (+100.0%) | 8.56M +8.6M (+100.0%) | 1.59% +1.586 pp | 1.04% +1.039 pp | USD17.12 +0.0% | 1 qtrs NEW |
| 18 | AMERICAN CENTURY COMPANIES INC | 417.5K +417.5K (+100.0%) | 7.15M +7.1M (+100.0%) | 1.32% +1.324 pp | 0.00% +0.004 pp | USD17.12 +0.0% | 1 qtrs NEW |
| 19 | GREAT POINT PARTNERS LLC | 325.0K +325.0K (+100.0%) | 5.56M +5.6M (+100.0%) | 1.03% +1.031 pp | 1.80% +1.804 pp | USD17.12 +0.0% | 1 qtrs NEW |
| 20 | FEDERATED HERMES, INC. | 325.0K +325.0K (+100.0%) | 5.56M +5.6M (+100.0%) | 1.03% +1.031 pp | 0.01% +0.009 pp | USD17.12 +0.0% | 1 qtrs NEW |
| 21 | KYNAM CAPITAL MANAGEMENT, LP | 185.5K +185.5K (+100.0%) | 3.18M +3.2M (+100.0%) | 0.59% +0.588 pp | 0.20% +0.203 pp | USD17.12 +0.0% | 1 qtrs NEW |
| 22 | ADAR1 CAPITAL MANAGEMENT, LLC | 184.1K +184.1K (+100.0%) | 3.15M +3.2M (+100.0%) | 0.58% +0.584 pp | 0.23% +0.231 pp | USD17.12 +0.0% | 1 qtrs NEW |
| 23 | MONASHEE INVESTMENT MANAGEMENT LLC | 183.2K +183.2K (+100.0%) | 3.14M +3.1M (+100.0%) | 0.58% +0.581 pp | 1.77% +1.768 pp | USD17.12 +0.0% | 1 qtrs NEW |
| 24 | SPHERA FUNDS MANAGEMENT LTD. | 166.1K +166.1K (+100.0%) | 2.84M +2.8M (+100.0%) | 0.53% +0.527 pp | 0.55% +0.550 pp | USD17.12 +0.0% | 1 qtrs NEW |
| 25 | SOFINNOVA INVESTMENTS, INC. | 153.3K +153.3K (+100.0%) | 2.62M +2.6M (+100.0%) | 0.49% +0.486 pp | 0.11% +0.113 pp | USD17.12 +0.0% | 1 qtrs NEW |
| 26 | BLACKROCK, INC. | 142.4K +142.4K (+100.0%) | 2.44M +2.4M (+100.0%) | 0.45% +0.452 pp | 0.00% +0.000 pp | USD17.12 +0.0% | 1 qtrs NEW |
| 27 | INTEGRAL HEALTH ASSET MANAGEMENT, LLC | 125.0K +125.0K (+100.0%) | 2.14M +2.1M (+100.0%) | 0.40% +0.397 pp | 0.11% +0.106 pp | USD17.12 +0.0% | 1 qtrs NEW |
| 28 | BIOIMPACT CAPITAL LLC | 113.0K +113.0K (+100.0%) | 1.93M +1.9M (+100.0%) | 0.36% +0.359 pp | 0.22% +0.221 pp | USD17.12 +0.0% | 1 qtrs NEW |
| 29 | GEODE CAPITAL MANAGEMENT, LLC | 109.8K +109.8K (+100.0%) | 1.88M +1.9M (+100.0%) | 0.35% +0.348 pp | 0.00% +0.000 pp | USD17.12 +0.0% | 1 qtrs NEW |
| 30 | AMERIPRISE FINANCIAL INC | 104.6K +104.6K (+100.0%) | 1.79M +1.8M (+100.0%) | 0.33% +0.332 pp | 0.00% +0.000 pp | USD17.12 +0.0% | 1 qtrs NEW |
| 31 | SEVEN GRAND MANAGERS, LLC | 75.0K +75.0K (+100.0%) | 1.28M +1.3M (+100.0%) | 0.24% +0.238 pp | 0.10% +0.098 pp | USD17.12 +0.0% | 1 qtrs NEW |
| 32 | STEMPOINT CAPITAL LP | 68.2K +68.2K (+100.0%) | 1.17M +1.2M (+100.0%) | 0.22% +0.216 pp | 0.20% +0.200 pp | USD17.12 +0.0% | 1 qtrs NEW |
| 33 | BALYASNY ASSET MANAGEMENT L.P. | 65.0K +65.0K (+100.0%) | 1.11M +1.1M (+100.0%) | 0.21% +0.206 pp | 0.00% +0.001 pp | USD17.12 +0.0% | 1 qtrs NEW |
| 34 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 62.7K +62.7K (+100.0%) | 1.07M +1.1M (+100.0%) | 0.20% +0.199 pp | 0.00% +0.000 pp | USD17.12 +0.0% | 1 qtrs NEW |
| 35 | GOLDMAN SACHS GROUP INC | 61.7K +61.7K (+100.0%) | 1.06M +1.1M (+100.0%) | 0.20% +0.196 pp | 0.00% +0.000 pp | USD17.12 +0.0% | 1 qtrs NEW |
| 36 | CAPRICORN FUND MANAGERS LTD | 60.0K +60.0K (+100.0%) | 1.03M +1.0M (+100.0%) | 0.19% +0.190 pp | 0.25% +0.248 pp | USD17.12 +0.0% | 1 qtrs NEW |
| 37 | CITADEL ADVISORS LLC | 50.6K +50.6K (+100.0%) | 865.6K +865.6K (+100.0%) | 0.16% +0.160 pp | 0.00% +0.000 pp | USD17.12 +0.0% | 1 qtrs NEW |
| 38 | BURKEHILL GLOBAL MANAGEMENT, LP | 50.0K +50.0K (+100.0%) | 856.0K +856.0K (+100.0%) | 0.16% +0.159 pp | 0.06% +0.056 pp | USD17.12 +0.0% | 1 qtrs NEW |
| 39 | TD ASSET MANAGEMENT INC | 44.6K +44.6K (+100.0%) | 764.1K +764.1K (+100.0%) | 0.14% +0.142 pp | 0.00% +0.001 pp | USD17.12 +0.0% | 1 qtrs NEW |
| 40 | POINT72 ASSET MANAGEMENT, L.P. | 34.4K +34.4K (+100.0%) | 588.7K +588.7K (+100.0%) | 0.11% +0.109 pp | 0.00% +0.001 pp | USD17.12 +0.0% | 1 qtrs NEW |
| 41 | TUDOR INVESTMENT CORP ET AL | 32.0K +32.0K (+100.0%) | 547.0K +547.0K (+100.0%) | 0.10% +0.101 pp | 0.00% +0.001 pp | USD17.12 +0.0% | 1 qtrs NEW |
| 42 | STATE STREET CORP | 31.5K +31.5K (+100.0%) | 539.3K +539.3K (+100.0%) | 0.10% +0.100 pp | 0.00% +0.000 pp | USD17.12 +0.0% | 1 qtrs NEW |
| 43 | QUBE RESEARCH & TECHNOLOGIES LTD | 24.1K +24.1K (+100.0%) | 411.9K +411.9K (+100.0%) | 0.08% +0.076 pp | 0.00% +0.000 pp | USD17.12 +0.0% | 1 qtrs NEW |
| 44 | NORTHERN TRUST CORP | 22.6K +22.6K (+100.0%) | 387.5K +387.5K (+100.0%) | 0.07% +0.072 pp | 0.00% +0.000 pp | USD17.12 +0.0% | 1 qtrs NEW |
| 45 | TWO SIGMA INVESTMENTS, LP | 21.3K +21.3K (+100.0%) | 365.1K +365.1K (+100.0%) | 0.07% +0.068 pp | 0.00% +0.001 pp | USD17.12 +0.0% | 1 qtrs NEW |
| 46 | OXFORD ASSET MANAGEMENT LLP | 19.6K +19.6K (+100.0%) | 335.0K +335.0K (+100.0%) | 0.06% +0.062 pp | 0.14% +0.136 pp | USD17.12 +0.0% | 1 qtrs NEW |
| 47 | XTX TOPCO LTD | 18.8K +18.8K (+100.0%) | 321.5K +321.5K (+100.0%) | 0.06% +0.060 pp | 0.01% +0.008 pp | USD17.12 +0.0% | 1 qtrs NEW |
| 48 | MANUFACTURERS LIFE INSURANCE COMPANY, THE | 10.2K +10.2K (+100.0%) | 179.1K +179.1K (+100.0%) | 0.03% +0.032 pp | 0.00% +0.000 pp | USD17.12 +0.0% | 1 qtrs NEW |
| 49 | MORGAN STANLEY | 8.3K +8.3K (+100.0%) | 142.9K +142.9K (+100.0%) | 0.03% +0.027 pp | 0.00% +0.000 pp | USD17.12 +0.0% | 1 qtrs NEW |
| 50 | UBS GROUP AG | 3.4K +3.4K (+100.0%) | 58.4K +58.4K (+100.0%) | 0.01% +0.011 pp | 0.00% +0.000 pp | USD17.12 +0.0% | 1 qtrs NEW |
| 51 | BANK OF AMERICA CORP /DE/ | 2.9K +2.9K (+100.0%) | 50.3K +50.3K (+100.0%) | 0.01% +0.009 pp | 0.00% +0.000 pp | USD17.12 +0.0% | 1 qtrs NEW |
| 52 | TOWER RESEARCH CAPITAL LLC (TRC) | 2.7K +2.7K (+100.0%) | 47.0K +47.0K (+100.0%) | 0.01% +0.009 pp | 0.00% +0.001 pp | USD17.12 +0.0% | 1 qtrs NEW |
| 53 | NATIONAL BANK OF CANADA /FI/ | 2.2K +2.2K (+100.0%) | 37.5K +37.5K (+100.0%) | 0.01% +0.007 pp | 0.00% +0.000 pp | USD17.12 +0.0% | 1 qtrs NEW |
| 54 | CHINA UNIVERSAL ASSET MANAGEMENT CO., LTD. | 2.0K +2.0K (+100.0%) | 34.2K +34.2K (+100.0%) | 0.01% +0.006 pp | 0.00% +0.003 pp | USD17.12 +0.0% | 1 qtrs NEW |
| 55 | ROYAL BANK OF CANADA | 585.00 +585.0 (+100.0%) | 10.0K +10.0K (+100.0%) | 0.00% +0.002 pp | 0.00% +0.000 pp | USD17.12 +0.0% | 1 qtrs NEW |
| 56 | LEGAL & GENERAL GROUP PLC | 400.00 +400.0 (+100.0%) | 6.8K +6.8K (+100.0%) | 0.00% +0.001 pp | 0.00% +0.000 pp | USD17.12 +0.0% | 1 qtrs NEW |
| 57 | COMERICA BANK | 20.00 +20.0 (+100.0%) | 330.00 +330.0 (+100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD17.10 +0.1% | 1 qtrs NEW |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 54 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Virtus Biotech Clinical Trials ETF BBC | 0.41% | 236.0K | 0.65% |
| 2 | ALPS Medical Breakthroughs ETF SBIO | 0.24% | 519.6K | 0.50% |
| 3 | American Century Small Cap Growth Insights ETF ACSG | 0.10% | 25.1K | 0.49% |
| 4 | iShares Micro-Cap ETF IWC | 0.04% | 563.4K | 0.60% |
| 5 | Fidelity Enhanced Small Cap ETF FESM | 0.01% | 635.8K | 0.28% |
| 6 | iShares Russell 2000 Growth ETF IWO | 0.01% | 1.58M | 0.24% |
| 7 | iShares Morningstar Small-Cap Growth ETF ISCG | 0.01% | 76.7K | 0.06% |
| 8 | Vanguard Russell 2000 Value ETF VTWV | 0.01% | 91.0K | 0.06% |
| 9 | Vanguard Russell 2000 ETF VTWO | 0.01% | 1.22M | 0.06% |
| 10 | Vanguard Russell 2000 Growth ETF VTWG | 0.01% | 118.4K | 0.06% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
-18.0K
Shares Outstanding
14.16M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Luis C. Pena | Founder, President, Chief Executive Officer & Director | 1M | male |
| Gregory S. Moss | Chief Business & Legal Officer, Corporate Secretary and Chief Compliance Officer | 1M | male |
| Kyle Carver | Chief Financial Officer | 1M | male |
| Daniel J. Burge | Senior Vice President of Clinical Development | — | — |
| Jeegar Patel | Chief Scientific Officer | — | — |
| Lou Sehl | Senior Vice President of Technical Operations | — | — |
| Janice Drew | Chief of Development Operations | — | female |
| Eugene Andrew Bauer | Co-Founder, Chief Medical Officer & Director | — | — |
| J. Mark Jackson | Senior Vice President of Clinical Development | — | male |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for EVMN
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
